PARADIGM-HEART FAILURE A POSSIBLE ALTERNATIVE TO ACE INHIBITORS
Dr. Milton Packer will be presenting these results for the first time in the United States at the HFSA Annual Meeting

LAS VEGAS (September 15, 2014) – The Heart Failure Society of America (HFSA) will host its 18th Annual Scientific Meeting that will feature a late breaking clinical trial which tested an Angiotensin Receptor Neprilysin inhibitor (ARNi) as a potential alternative to Angiotensin converting enzyme (ACE) inhibitors. The session will take place on Monday, September 15th at 4:45 PM, and will be led by Dr. Milton Packer, MD.

The session will focus on the late breaking trial that Dr. Packer led over a period of five years that involved 8,400 patients coming from 1,000 sites throughout 47 countries who were diagnosed with heart failure and a reduced ejection fraction. Rather than focusing on the conventional method of using ACE inhibitors to prolong life, Dr. Packer decided to substitute a different approach by using a drug, LCZ696 which is a combination of ARNi and Angiotensin receptor blockers, that could ultimately replace ACE inhibitors and result in higher outcomes of prolonged life than ACE inhibitors.

“ACE inhibitors have been the cornerstone of treatment for heart failure for 25 years, but instead of assuming this standard method of treatment, we decided our goal was to show that LCZ696 works better than ACE inhibitors,” said Dr. Packer. “While ACE inhibitors decrease the ‘bad’ enzymes, our intent was to be the first team to design a drug that not only decreases the bad but simultaneously increases the good. This trial is poised to change management of heart failure for years to come and we are pleased to present our results at the HFSA annual meeting.”

Top line results of Dr. Packer’s trial were recently presented at the Barcelona European Society of Cardiology. During his presentation at the HFSA meeting, Dr. Packer will be rolling out additional findings from his research to prove the benefits that LCZ696 has, which will be the first time these results have been presented in the United States. Additionally, following the late breaking clinical trial session, there will be a short discussion focused on the potential clinical implications of the paradigm heart failure study.

For a complete list of annual meeting sessions or for details on attending the conference, visit www.hfsa.org and click on Annual Scientific Meeting. There is also an app for the Annual Meeting available in the Apple Store by searching HFSA. There is no registration fee for accredited journalists.
Interview areas will be available on-site in addition to a press room. You may follow news from the meeting on Twitter @HFSA and #HFSA.

###

**About Heart Failure**

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit [www.abouthf.org](http://www.abouthf.org).

**About the Heart Failure Society of America**

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. The HFSA provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at [www.hfsa.org](http://www.hfsa.org).